About The Study: In this study, over a median of 8.6 years, low-dose aspirin was not associated with incident cancer among older adults, but cancer mortality risk was significantly elevated. However, the elevated cancer mortality risk seen with aspirin for participants in the randomized clinical trial (RCT) period did not persist into the post-RCT observation period, suggesting no legacy effect.
Corresponding Author: To contact the corresponding author, Suzanne G. Orchard, PhD, email suzanne.orchard@monash.edu .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamaoncol.2025.6196)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2025.6196?guestAccessKey=9e0e2bf2-a97e-4f0c-95df-7de0e7b22c1e&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=012926
JAMA Oncology